Osteoarthritis or arthritis? Toward understanding of primary Sjögren’s syndrome patients with arthralgia

Gao, Ren; Pu, Jincheng; Wu, Zhenzhen; Tang, Jianping; Wang, Xuan

doi:10.1186/s13018-023-03513-1

Cited by 2 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Musculoskeletal involvement is present in the majority of pSS patients, consisting of arthralgias, arthritis, and myalgias [ 69 ]. The prevalence of arthralgia is up to 96% [ 70 ], whereas arthritis has been reported in 16.6% [ 71 ]. Arthralgias may appear concurrently with the sicca symptoms and correlate with anti-Ro/SSA anti-La/SSB antibodies positivity [ 72 ].…”

Section: Extraglandular Manifestationsmentioning

confidence: 99%

The Spectrum of Extraglandular Manifestations in Primary Sjögren’s Syndrome

Mihai

Căruntu

Jurcuţ

et al. 2023

JPM

View full text Add to dashboard Cite

Extraglandular manifestations (EGMs) in primary Sjogren’s syndrome (pSS) represent the clinical expression of the systemic involvement in this disease. EGMs are characterized by a wide heterogeneity; virtually any organ or system can be affected, with various degrees of dysfunction. The existing gaps of knowledge in this complex domain of extraglandular extension in pSS need to be overcome in order to increase the diagnostic accuracy of EGMs in pSS. The timely identification of EGMs, as early as from subclinical stages, can be facilitated using highly specific biomarkers, thus preventing decompensated disease and severe complications. To date, there is no general consensus on the diagnostic criteria for the wide range of extraglandular involvement in pSS, which associates important underdiagnosing of EGMs, subsequent undertreatment and progression to severe organ dysfunction in these patients. This review article presents the most recent basic and clinical science research conducted to investigate pathogenic mechanisms leading to EGMs in pSS patients. In addition, it presents the current diagnostic and treatment recommendations and the trends for future therapeutic strategies based on personalized treatment, as well as the latest research in the field of diagnostic and prognostic biomarkers for extraglandular involvement in pSS.

show abstract

Section: Extraglandular Manifestationsmentioning

confidence: 99%

The Spectrum of Extraglandular Manifestations in Primary Sjögren’s Syndrome

Mihai

Căruntu

Jurcuţ

et al. 2023

JPM

View full text Add to dashboard Cite

show abstract

Polyarthritis in Sjögren’s Syndrome: Difficulties in Distinguishing Extraglandular Manifestation and Associated Rheumatoid Arthritis

Aradi,

Nagy,

Horváth

et al. 2024

Diagnostics

View full text Add to dashboard Cite

Aim of the study was to investigate the demographic data and disease course characteristics of patients with Sjögren’s syndrome (SS) and inflammatory joint pain of various origins and to search for factors that might help with the distinction of polyarthritis as an extraglandular manifestation and rheumatoid arthritis as an associated systemic autoimmune disorder. A total of 355 patients were retrospectively analyzed, 128 of whom served as controls (SS-C), while 159 had polyarthritis as an extraglandular symptom of Sjögren’s syndrome (SS-pa) and 68 were diagnosed as having associated rheumatoid arthritis (SS-RA). The patients without any inflammatory joint manifestations were significantly older than the SS-pa patients, while, for the SS-RA group, the difference was not significant. The onset of joint pain appeared significantly earlier in the SS-RA patients. Regarding either extraglandular manifestations or associated autoimmune disorders, there were significant differences between the controls and both SS-pa and SS-RA groups, while no significant difference was found between the SS-pa and SS-RA groups. Thus, laboratory and imaging methods should be used to differentiate between the two conditions, but laboratory biomarkers are even more important for early diagnosis. A ROC curve analysis showed an acceptable diagnostic accuracy in differentiating between SS-pa and SS-RA patients using a binary logistic regression model, where highly positive rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) values, kidney involvement, and anti-Ro/SS-A positivity were shown to significantly raise the odds of having RA, whereas anti-La/SS-B positivity seemed to have a protective role, since it significantly decreased the odds of having it. Further biomarkers are needed to better classify SS patient cohorts with inflammatory joint pain of different origins and, consequently, different management requirements.

show abstract

Osteoarthritis or arthritis? Toward understanding of primary Sjögren’s syndrome patients with arthralgia

Cited by 2 publications

References 44 publications

The Spectrum of Extraglandular Manifestations in Primary Sjögren’s Syndrome

The Spectrum of Extraglandular Manifestations in Primary Sjögren’s Syndrome

Polyarthritis in Sjögren’s Syndrome: Difficulties in Distinguishing Extraglandular Manifestation and Associated Rheumatoid Arthritis

Contact Info

Product

Resources

About